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Abstract Mutagenicity refers to the induction of permanent
changes in the DNA sequence of an organism, which may
result in a heritable change in the characteristics of living
systems. Antimutagenic agents are able to counteract the
effects of mutagens. This group of agents includes both natu-
ral and synthetic compounds. Based on their mechanism of
action among antimutagens, several classes of compounds
may be distinguished. These are compounds with antioxidant
activity; compounds that inhibit the activation of mutagens;
blocking agents; as well as compounds characterized with
several modes of action. It was reported previously that sev-
eral antitumor compounds act through the antimutagenic
mechanism. Hence, searching for antimutagenic compounds
represents a rapidly expanding field of cancer research. It may
be observed that, in recent years, many publications were
focused on the screening of both natural and synthetic com-
pounds for their beneficial muta/antimutagenicity profile.
Thus, the present review attempts to give a brief outline on
substances presenting antimutagenic potency and their possi-
ble mechanism of action. Additionally, in the present paper, a
screening strategy for mutagenicity testing was presented and
the characteristics of the most widely used antimutagenicity
assays were described.
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Introduction
The genomes of all living organisms are constantly subjected
to damage by both external agents and endogenous processes,
such as spontaneous DNA damage. Mutagenicity refers to the
induction of permanent changes in the DNA sequence of an
organism, which may result in a heritable change in the
characteristics of living systems. Mutations may alter a single
gene, a block of genes, or whole chromosomes. Point (gene)
mutations affect only one nucleotide or a few nucleotides
within a gene. Point mutations, which are the most common
type of alteration in the DNA sequence, can be divided into
three main types: a base pair substitution (the replacement of
one base pair with another); a deletion (the loss of one or more
base pairs); and an insertion (the addition of extra base pairs
into the DNA sequence).
The term “genotoxicity” is a broader concept than mutage-
nicity and describes the capacity of the compounds to affect
the DNA structure or the cellular apparatus and
topoisomerases, which are responsible for the genome fidelity.
Genotoxic effects on DNA are not always related to mutations
(Maurici et al. 2005; Eastmond et al. 2009).
Mutations are created mainly by external factors, including
chemical and physical agents, called mutagens. Additionally,
mutations can occur spontaneously due to errors in DNA
replication, repair, and recombination. In general, mutations
can be grouped into negative, neutral, positive, lethal, and sub-
lethal. Mutagenic changes that occur in germline cells can be
passed to future generations, whereas somatic mutations may
contribute to the pathogenesis of various pathological condi-
tions, including cancer (Migliore and Coppedè 2002; Cooke
et al. 2003; Izzotti et al. 2003; Weakley et al. 2010).
Antimutagenic agents are able to counteract the effects of
mutagens. Therefore, knowledge on the mode of action of
certain mutagenic compounds provides a basis for an expla-
nation of how antimutagenic compounds work.
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Identifying the antimutagenic compounds is among the
most promising area of research in recent years. Therefore,
in this review, the substances presenting antimutagenic activ-
ity are presented, with special emphasis on their mechanisms
of action (Fig. 1). Moreover, the present paper is concerned
with the screening strategy for mutagenicity testing and the
most popular assays used in antimutagenicity testing.
Mutagens
The term “mutagen” refers to the chemical or physical agent
that is capable of inducing changes in the genetic material of an
organism. Consequently, the number of mutation events is
increased above the backgroundmutation frequency. As chem-
ical mutagens induce mutations by different mechanisms, sev-
eral major classes of them, such as alkylating agents, base
analogs, and intercalating agents, can be distinguished.
Alkylating agents such as N-methyl-N ′-nitro-N-
nitrosoguanidine (MNNG) and ethyl methanesulfonate (EMS)
are able to react with DNA bases directly and transfer an alkyl
group to form monoadducts in genetic material. Consequently,
DNA strand breaks are produced, causing specific mispairing
(Ralhan andKaur 2007). Themost frequent location of adducts in
DNA is at guanine, leading to the formation of O6-alkylguanine
(Sanderson and Shield 1996). Noteworthy, some of the alkylating
agents, such as cyclophosphamide (CP), are used for the treat-
ment of cancer. Base analogs are molecules that have similar
structure to normal DNA bases and, thereby, can substitute a base
in geneticmaterial, leading to transitions and tautomerization. For
example, 5-bromouracil (5-BU) is an analog of thymine, whereas
2-amino-purine (2-AP) is an analog of adenine. It should be noted
that various base analogs are used as anticancer agents and
immunosuppressants. Finally, intercalating agents such as acri-
dine mutagen ICR-191 mimic base pairs and are able to insert
between DNA bases at the core of the DNA double helix. This
results in single-nucleotide pair insertions and deletions.
Many mutagenizing agents known as direct-acting muta-
gens. such as sodium azide (NaN3), affect genetic material
directly, leading to structural damage; on the other hand, some
compounds, including benzo[α]pyrene (BP), act on DNA in
an indirect manner (indirect-actingmutagens) via the induction
of the synthesis of different chemicals which influence DNA
directly. During this process, the transformation of promutagen
into the actual mutagen takes place. Table 1 depicts selected
chemical mutagens and their mechanisms of action.
Antimutagens
Certain compounds, known as antimutagens, are able to de-
crease or even remove the mutagenic effects of potentially
Fig. 1 Mechanisms of action of
antimutagens
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harmful chemicals. Novick and Szilard (1952) primarily ap-
plied the term “antimutagen” to agents possessing the ability
to diminish the rate or frequency of induced or spontaneous
mutations. This group of agents includes both natural and
synthetic compounds. According to Kada et al. (1982), two
different types of antimutagens, i.e., desmutagens and
bioantimutagens, can be distinguished. Desmutagens that
function extracellularly are able to inactivate mutagenic agents
before they reach DNA. On the other hand, bioantimutagens
act within the cell and participate inmutation suppression after
DNA damage. These compounds are able to influence ge-
nome repair and replication (Kada and Shimoi 1987; De Flora
1998). Based on their mechanism of action among
antimutagens, several classes of compounds may be distin-
guished. These are compounds with antioxidant activity; com-
pounds that inhibit the activation of mutagens; blocking
agents; as well as compounds characterized with several
modes of action. Examples of some recently described
antimutagenic compounds and their possible modes of action
are presented in Table 2.
It was reported previously that several antitumor com-
pounds act through the antimutagenic mechanism (Tsai et al.
1996; Dion et al. 1997; Ikken et al. 1999). Hence, searching
for antimutagenic compounds represents a rapidly expanding
Table 1 Selected chemical mutagens and their mechanisms of action
Mutagen Kind of mutagen Mechanism of action Reference
N-acetyl-2-aminofluorene (AAF) Indirect acting - Reacts with guanines at the C8 position in DNA to
form a structure that interferes with DNA replication
Gill and Romano (2005)
Acridine (AC) Direct acting - At low concentrations binds DNA tightly but reversibly
by intercalation
- At high concentrations induces DNA strand breaks
Ferguson and Denny
(2007)
9-aminoacridine (9-AA) Direct acting - Induces frameshift mutations at hot spots where a single
base, especially guanine, is repeated
- Binds to DNA noncovalently by intercalation
Ferguson and Denny
(2007)
Hoffmann et al. (2003)
2-aminoanthracene (2-AA) Indirect acting - Its electrophilic reactive metabolites form DNA adducts So et al. (2008)
Sugamori et al. (2006)
2-aminofluorene (2-AF) Indirect acting - Is converted to reactive carcinogenic ester
2-acetylaminofluorene-N-sulfate, which
can attack guanine residues in nucleic acids
DeBaun et al. (1970)
Aflatoxin B1 (AFB1) - Stimulates the release of free radicals, which
cause chromosomal aberrations
Alpsoy et al. (2009)
Benzo(α)pyrene (BP) Indirect acting - An active mutagen is benzo[a]pyrene-7,8-diol-9,
10-epoxide (BPDE)
- Major adducts of BP-DNA are BPDE-deoxyguanosine
(dG) and 9-OH-BP-dG-derived adducts
Smith and Gupta (1996)
Cyclophosphamide (CP) Indirect acting - Affects DNA through its alkylating properties
and free radical production
Zhang et al. (2005)
Doxorubicin (DXN) Direct acting - Induces G:C–T:A transversions
- Undergoes electron reduction and leads to the
generation of free radical species
Koch et al. (1994)
Singal et al. (2000)
Ethyl methanesulfonate (EMS) Direct acting - An alkylating agent
- At low concentrations alters a base in DNA




Achary and Panda (2010)
Methyl methanesulfonate (MMS) Direct acting - An alkylating agent
- Modifies guanine and adenine to cause base mispairing




Direct acting - Leads to the alkylation of purines and pyrimidines
- One of the most important products of MNNG is
O6-methylguanine
Koch et al. (1994)
Kumaresan et al. (1995)
Gulluce et al. (2010)
4-nitro-o-phenylenediamine (NPDA) Direct acting - Induces frameshift mutations Koch et al. (1994)
1-nitropyrene (1-NP) Direct acting - Forms DNA adduct N-(deoxyguanosine-8-yl)-1-aminopyrene Bacolod and Basu (2001)
4-nitroquinoline-N-oxide (NQNO) Direct acting - A base substitution agent, principally acting at G residues,
inducing mainly GC to AT transitions
Fronza et al. (1992)
Sodium azide (NaN3) Direct acting - Mutagenicity is mediated through the production of
an organic metabolite (L-azidoadenine) that enters the
nucleus and then interacts with DNA and originates
point mutations in the genome
- Induces G:C→A:T transitions
Koch et al. (1994)
Al-Qurainy and Khan
(2009)
Gulluce et al. (2010)
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field of cancer research (Heo et al. 2001; Ferguson and Philpot
2008; El-Sayed and Hussin 2013; El-Sayed et al. 2013).
Interestingly, certain compounds exhibit dual nature and
display both antimutagenic and mutagenic effects. Such com-
pounds are known as “Janus mutagens”, after the Roman god
who had one head with two faces looking in opposite direc-
tions (von Borstel and Higgins 1998; Zeiger 2003). β-
carotene (βCT) belongs to this group of compounds. Its dual
nature can be attributed primarily to the fact that βCT pos-
sesses the ability to both scavenge and produce free radicals
(Paolini et al. 2003).
Antimutagens with antioxidant potency
As many mutagens act through the generation of reactive
oxygen species (ROS), the removal of reactive molecules
represents an important strategy in the process of
antimutagenesis (Shay et al. 2009; Tian et al. 2012). There is
increasing evidence that compounds with antioxidant proper-
ties can remove ROS before these molecules react with DNA,
resulting in a mutation (Lee et al. 2011; Tian et al. 2012).
Unal et al. (2013), who investigated the antigenotoxic
effects of lipoic acid (LA) against mitomycin-C induced
Table 2 Examples of some recently described antimutagenic compounds and their mechanisms of action
Antimutagen Mechanism of action Reference
Cysteine - Direct chemical interaction with a mutagen Watanabe et al. (1994)
Gallic acid - Scavenging of the electrophilic mutagens
- Binding or insertion into the outer membrane transporters,
leading to the blockage of a mutagen that was
transferred into the cytosol
Hour et al. (1999)
Lipoic acid - Antioxidant potency Unal et al. (2013)
Phenolics - Interference with cytochrome P450-mediated metabolism
of mutagens
- Interaction with active mutagenic metabolites
- DNA protection against mutagens presenting electrophilic properties
De Flora et al. (2001)
Marnewick et al. (2000)
Acacia salicina - Antioxidant effects
- Direct interaction with mutagens electrophilic metabolites
- Influence on the enzymes engaged in the metabolism of mutagens
Chatti et al. (2011)
Boubaker et al. (2011)
Acanthopanax divaricatus var. albeofructus
(ADA) extracts
- Rapid elimination of mutagenic compounds from the cells
before the induction of DNA damage
Hong et al. (2011)
Lichen species - Antioxidant activity Nardemir et al. (2013)
Agar et al. (2010)
Gulluce et al. (2010)
Mangifera indica L. stem bark (MSBE) - Antioxidant activity
- Inhibition of the metabolic activation of promutagens
Morffi et al. (2012)
Phellinus rimosus extract - Direct inactivation of mutagens




Phytoconstituents from Terminalia arjuna - Inhibition of the metabolic activation of promutagens Kaur et al. (2010)
Powder of grain (Lisosan G) - Antioxidant effects Frassinetti et al. (2012)
Wheat bran - Antioxidant potency
- Modulation of DNA-repairing enzymes
Pesarini et al. (2013)
Xanthones and flavones of Syngonanthus
(Eriocaulaceae)
- Elimination of mutagens from bacteria
- Interaction with reactive intermediates of mutagens
- The influence on microsomal enzymes
de Oliveira et al. (2013)
β-aminoketones - Inhibition of the metabolic activation of promutagens
- The blockage of mutagens binding to DNA
Gulluce et al. (2010)
Hoffmann et al. (2003)
Bichalcophenes - Binding to DNA and protection against electrophilic mutagens
- Interaction with mutagens
- Antioxidant activity
Marnewick et al. (2000)
Watanabe et al. (1994)
Collins et al. (2012)
Luteoline derivatives - Protection against DNA double-strand breaks
- Protection against mutagens intercalating effects or
alkylating action
Orhan et al. (2013)
Nitrogen- and oxygen-containing
heterocyclic compounds
- Inhibition of the metabolic activation of promutagens Turhan et al. (2012)
Organoselenium compounds - Antioxidant potency Roy et al. (2012)
Pyrrolidine-2,5-dione derivatives - Direct interaction with a mutagen Pękala et al. (2013)
Aminoalkanolic derivatives of xanthones - Direct interaction with a mutagen Słoczyńska et al. (2010)
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chromosomal aberrations, sister chromatid exchanges, and
micronucleus formation in human peripheral lymphocytes,
demonstrated that LA exhibits both anticlastogenic and
antimutagenic activity. The use of several assays in studies
on LA antigenotoxicity revealed the comprehensive action of
this compound against genetic damage. These beneficial ef-
fects can be primarily attributed to the antioxidant potency of
LA. Additionally, it was suggested that LA improves the DNA
repair system or DNA synthesis. This is consistent with pre-
vious reports describing LA as a highly potent antioxidant that
plays numerous roles in removing ROS (Evans and Goldfine
2000; Cai et al. 2013; Rochette et al. 2013).
In another study, Nardemir et al. (2013) stated that the
antimutagenic action of selected lichen species may be related
to the inhibitory activity of the lichen extracts on the formation
of free radicals. This was confirmed by its influence on
superoxide dismutase (SOD) and glutathione peroxidase
(GPx) activity, as well as the glutathione (GSH) and
malondialdehyde (MDA) levels. Thus, lichen species may
protect DNA from genetic damage through the restoration of
natural antioxidant defense mechanisms. Other authors also
confirmed that the antimutagenic activity of the lichen extracts
is closely related to antioxidant effects (Agar et al. 2010;
Kotan et al. 2011). Another example of an antimutagen of
natural origin acting mainly through its antioxidant proper-
ties is Acacia salicina, the extracts of which provide protec-
tion against DNA strand scission induced by the hydroxyl
radical. The tested extracts decreased significantly the muta-
genicity induced by LA and 4-nitro-o-phenylenediamine
(NPDA) (Chatti et al. 2011). The observed antigenotoxic
potency could be ascribed, at least in part, to their antioxi-
dant effects.
Some antimutagenic compounds are not potent antioxi-
dants on their own but can be converted into molecules that
display antioxidant activity. Such phenomena was observed
for several amino acid conjugates of curcumin that demon-
strated very high antimutagenic activity with mutagens such
as NaN3 and methyl methanesulfonate (MMS) against
Salmonella typhimurium strains (Parvathy et al. 2010).
Moreover, the antimutagenic activity of a powder of grain
(Lisosan G) in yeast Saccharomyces cerevisiae was attributed
primarily to the antioxidant potency of Lisosan G polyphenols
(Frassinetti et al. 2012).
The search for synthetic antimutagens is another important
trend in the area of antimutagenicity research. For example,
Roy et al. (2012) demonstrated that a series of organoselenium
compounds protected against genotoxicity and oxidative
stress induced by an indirect-acting mutagen CP (Roy et al.
2012). As CP affects DNA through it alkylating properties and
free radicals production (Zhang et al. 2005), the tested com-
pounds may act through multiple antioxidant mechanisms,
including the influence on the activity of SOD and catalase
(CAT), the level of GSH, and the removal of ROS. Recently,
also, the novel bichalcophenes significantly decreased the
mutagenicity induced by two mutagens, namely, NaN3 and
BP (El-Sayed and Hussin 2013). It was found that the
antimutagenic potential of the compounds could be attributed
to their antioxidant activity (Collins et al. 2012).
Based on current knowledge, antioxidant activity is a de-
sirable property, since it can be attributed to the antimutagenic
effects of compounds. Thus, it would be vital to test the
antimutagenic potential of any compound that displays anti-
oxidant activity.
Antimutagens that inhibit the activation of mutagens
The mutagenic effect of promutagens is dependent on their
metabolic activation, which is mediated mainly by phase I
metabolic enzymes, such as the cytochrome P450 family of
enzymes. Some antimutagens are able to inhibit the enzymes
responsible for the biotransformation of mutagenic com-
pounds, leading to the inhibition of promutagens
bioactivation.
Recently, the antimutagenic potential of some newly syn-
thesized nitrogen- and oxygen-containing heterocyclic com-
pounds against NaN3 andMNNGwas demonstrated using the
Ames/Salmonella and Escherichia coliWP2 bacterial reverse
mutation assay systems (Turhan et al. 2012). The
antimutagenic activity of the tested compounds was probably
due to the inhibition of L-azidoalanine and O6-methylguanine
formation.
With reference to natural antimutagens, Nardemir et al.
(2013) observed that the methanol extracts of the lichens have
shown antimutagenic effects against NaN3, whichmight result
from the extract inhibition of the production of NaN3 metab-
olite, known as L-azidoalanine (Gulluce et al. 2010). In an-
other study, phytoconstituents isolated from Terminalia arjuna
suppressed the mutagenic effect of the aromatic amine, i.e., 2-
aminofluorene (2-AF) (Kaur et al. 2010). The observed activ-
ity was found to be a consequence of the inhibition of the
metabolic activation of 2-AF to the mutagenic forms. The
mutagen activation is connected with N-oxidation by cyto-
chrome P4501A2; next, the activation by N-acetyltransferase
takes place (Beudot et al. 1998). Also, in the case of isothio-
cyanates, the main mechanism of their antimutagenicity is
related to the inhibition of the metabolic activation of muta-
gens via the influence on cytochrome P4501A1 and 1A2
activity (Hamilton and Teel 1995).
Antimutagens as blocking agents
Another important protective mechanism against chemical
mutagenesis is related to the direct chemical interaction
between an antimutagenic compound and a mutagen before
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i t induces DNA damage. In that way, 3-chloro-
4-(dichloromethyl)-5-hydroxy-2(5H)-furanone (MX) was
inactivated using various sulfhydryl compounds, such as
cysteine (Watanabe et al. 1994). Blocking agents are also
able to prevent mutagenic compounds from reaching target
sites. For example, nucleophilic bichalcophenes might be
able to bind to DNA and, therefore, protect genetic material
from electrophilic mutagenic agents (Marnewick et al.
2000) . Another hypothes i s for b icha lcophenes
antimutagenic potential might be that these compounds
are able to directly interact with mutagens, leading to the
inhibition of their damaging activity (Watanabe et al. 1994).
Hour et al. (1999), who examined the antimutagenic prop-
erties of gallic acid by the Ames test, found that this com-
pound could perhaps act as a nucleophile to scavenge the
electrophilic mutagens. Moreover, it was implied that gallic
acid can bind or insert into the outer membrane transporters
and lead to the blockage of a mutagen that was transferred into
the cytosol. In another study, Acanthopanax divaricatus var.
albeofructus (ADA) extracts displayed antimutagenic activity
against direct-acting mutagenic agents through the rapid elim-
ination of mutagenic compounds from the cells before the
induction of genetic material damage (Hong et al. 2011).
Antimutagens with multiple mechanisms of action
A great variety of antimutagenic agents act through multiple
mechanisms to provide protection against diverse mutagens.
Noteworthy, the ability of compounds to affect mutagens
simultaneously in several different ways significantly increase
antimutagenic effectiveness. Hence, searching for such
multifunctionally acting antimutagens is of great importance.
In the study conducted by Ozturkcan et al. (2012), the
antigenotoxic potential of two newly synthesized β-
aminoketones against MNNG and 9-aminoacridine (9-AA)-
induced mutagenesis was evaluated. The findings of the
study provided information about chemical prevention from
the toxicity of both mutagens by using selected compounds.
The study elicited that two newly synthesized β-
aminoketones , namely, 2-{(4-bromophenyl) [ (4-
methylphenyl)amino]methyl}cyclohexanone and 2-{(4-
chlorophenyl)[(4-methylphenyl)amino]methyl}cyclo-
hexanone, demonstrated antimutagenic action against muta-
genicity induced by MNNG, a mutagen acting by DNA
methylation. The antimutagenic potential of these com-
pounds may be related to the inhibition of the production
of O6-methylguanine, a product of MNNG that is related to
its mutagenic effect (Eadie et al. 1984; Gulluce et al. 2010).
In addition, the study showed that both compounds also
abolished mutagenesis induced by 9-AA that binds to DNA
noncovalently by intercalation. Consequently, frameshift
mutations at hotspots are formed, leading to the repetition
of a single base, mainly guanine (Hoffmann et al. 2003).
Thus, the antimutagenic effect of β-aminoketones might be
explained on the basis of the blockage of mutagen binding to
DNA.
In another study, Ajith and Janardhanan (2011) demonstrat-
ed the in vitro antimutagenic activity of ethyl acetate extract of
macro fungus, Phellinus rimosus, using the Ames assay. It
was concluded that the antimutagenic potential of the extract
against direct-acting mutagens may result from the direct
inactivation of mutagens. It is probable that, due to stimulation
of the transmembrane export system in bacteria, mutagenic
compounds are removed from the cells before they influence
the DNA structure. Additionally, in the case of doxorubicin
(DXN), the extract ofP. rimosusmay affect the intercalation of
mutagens to genetic material. The antimutagenic effect of the
extract against indirect-acting mutagen BP may be partially
ascribed to the inhibition of the mixed-function oxidase
(MFO) system and also to the conjugation of the components
of the extract with benzo[a]pyrene-7,8-diol-9,10-epoxide
(BPDE), being a BP-active mutagen. Moreover, the inhibition
of 2-AF-induced mutagenesis might be related to the MFO
inhibition or inactivation of the reactive carcinogenic ester of
2-AF, namely, 2-acetylaminofluorene-N-sulfate, which is ca-
pable of attacking guanine residues in nucleic acids. In case of
both types of mutagens (direct and indirect), the extract of
P. rimosus may remove free radical species generated by
certain mutagens, such as DXN and BP.
Boubaker et al. (2011) demonstrated that extracts of Acacia
salicina display potent antioxidant and antimutagenic activi-
ties. Chloroform extract was antimutagenic against both
direct- and indirect-acting mutagens, as the extract may serve
as a blocking agent that is capable of influencing the activities
of enzymes engaged in the metabolism of mutagens and
carcinogens. Moreover, the tested extract displayed the ability
to react directly with the mutagen’s electrophilic metabolites
and was capable of protecting against oxidative DNA damage.
In another study, Morffi et al. (2012) investigated the
antimutagenic effects of Mangifera indica L. stem bark
(MSBE) extract against DNA damage induced by ten different
mutagenic agents in the Ames test. MSBE is a Cuban nutra-
ceutical supplement rich in polyphenols. It was observed that
MSBE protected against genetic material damage induced by
all the tested mutagens, except for NaN3. This DNA protec-
tion may be due to the antioxidant activity of MSBE. In
addition, the antimutagenic properties of the extract may be
explained by the influence ofMSBE upon the CYP subfamily.
Pesarini et al. (2013) examined the antimutagenic effects of
wheat bran and concluded that such properties may be mainly
related to the presence of the antioxidant phytic acid. It was
demonstrated that phytic acid may intercept carcinogenic
azoxymethane, inhibiting it even before it can damage DNA.
Moreover, antioxidants included in wheat bran are able to
modulate DNA repair enzymes.
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In the case of heterocyclic aromatic amines (HAAs), it was
proved that the attenuation of their unfavorable mutagenic
effect might result from the influence on the DNA repair
pathway, the stimulation of detoxifying enzymes, and the
inhibition of enzymes that participate in the metabolic activa-
tion of HAAs (Schwab et al. 2000).
Phenolics are able to act against mutagens via both intra-
cellular and extracellular mechanisms (De Flora 1998; De
Flora et al. 2001). The extracellular mechanism involves
interference with the cytochrome P450-mediated metabolism
of these mutagens and the interaction with active mutagenic
metabolites (Marnewick et al. 2000). Furthermore, the
antimutagenic potency of these compounds may be related
to DNA protection from mutagens presenting electrophilic
properties (Marnewick et al. 2000).
In another experiment, the antimutagenic potential of
luteoline derivatives (luteolin-7-O-glucoside, luteolin-7-O-
rutinoside, and luteolin-7-O-glucuronide) against acridine
(AC) was explained by the fact that these derivatives are able
to stop the production of DNA double-strand breaks or AC
intercalating effects. In addition, the inhibition effects against
ethyl methanesulfonate (EMS) may be related to the protec-
tion against DNA double-strand breaks or EMS alkylating
action (Orhan et al. 2013).
The antimutagenic potential of xanthones and flavones of
Syngonanthus (Eriocaulaceae) was stated with recombinant
yeast assay (RYA) and the Ames test (de Oliveira et al. 2013).
This beneficial activity may be attributed to different mecha-
nisms, such as the rapid elimination of mutagens from bacte-
ria; the interaction between antimutagens and the reactive
intermediates of mutagens; and the influence on microsomal
enzymes.
With reference to synthetic compounds, in our team, we
eva lua ted the an t imutagenic ac t iv i ty of some
aminoalkanolic derivatives of xanthones and some new
derivatives of pyrrolidine-2,5-dione with antiepileptic ac-
tivity (Słoczyńska et al. 2010; Pękala et al. 2013). These
compounds were tested with the Vibrio harveyi assay
against direct mutagen 4-nitroquinoline-N-oxide (NQNO).
According to the results obtained, two of the tested xan-
thone derivatives presented beneficial antimutagenic poten-
tial. As for derivatives of pyrrolidine-2,5-dione, some of
them had strong or moderate antimutagenic activity against
NQNO. In general, one may speculate that the core struc-
tures of the test compounds may suggest their possible
interactions with NQNO, thus preventing mutagenic activ-
ity, similarly to previously reported mechanisms of
antimutagenic activities of caffeine and other methylxan-
thines (Ulanowska et al. 2005, 2007; Ulanowska and
Węgrzyn 2006).
In summary, it seems that the interest in antimutagenic
substances displaying multiple mechanisms of action is deter-
mined by the universality of their action and will be an
important trend in the research and development of new
antimutagenic compounds in the near future.
Mutagenicity testing strategy
For any compound that is a candidate for use as a therapeutic
agent, it is vital that it does not display mutagenic potency.
Additionally, compounds presenting antimutagenic properties
may be able to modulate or reduce the mutagenic effects of
some chemicals.
In the field of drug discovery, mutagenicity data are re-
quired for the pharmaceuticals before the commencement of
clinical trials and marketing authorization. The screening
strategy for mutagenicity testing is based on a battery of tests
and includes both in vitro and in vivo assays, according to the
results obtained. The above approach ensures that a wide
variety of genetic damage such as gene mutation, chromo-
somal damage, and aneuploidy can be identified. Noteworthy,
both in vitro and in vivo testing methods are used to identify
the same endpoints. The European Union has already imple-
mented this strategy; additionally, guidelines have been rec-
ommended internationally (Combes et al. 2007).
In general, mutagenicity assessment can be divided into
three phases. Phase 1 is based upon in vitro tests that are
performed with cultured bacterial and mammalian cells;
Phase 2 involves the assessment of mutagenic activity
in vivo in somatic cells; and, finally, Phase 3 assays screen
for germ cell mutagens (Eastmond et al. 2009; Valdiglesias
et al. 2010). Recommended protocols for the suitable tests are
given in the Organisation for Economic Co-operation and
Development (OECD) guidelines and the International
Workshops on Genotoxicity Testing (IWGT) guidance.
Phase 1 assays employ bacteria and mammalian cells and
are used for the identification of gene mutations and chromo-
some alterations. In the early mutagenicity assessment, two or
three different tests in bacteria and mammalian cells should be
used. The bacterial mutation assays such as Salmonella
typhimurium and Escherichia coliWP2 reverse mutation tests
are a useful tool for point mutations identification. These
assays allow for the detection of new mutations which are
able to revert old mutations existing in tester strains.
Mammalian mutation assays are useful especially in case of
bactericidal compounds and agents acting preferentially on
the replication system in mammals. Common Phase 1 in vitro
mammalian tests include: the mouse lymphoma thymidine
kinase (TK) gene mutation assay, which detects compounds
that induce forward gene mutations in the tk gene of the
L5178Y mouse lymphoma cell line, and the hypoxanthine
guanine phosphorybosyl transferase (HPRT) gene mutation
assay, which identifies agents that cause gene mutations in the
hprt gene of a suitable cell line, such as Chinese hamster cells
(Combes et al. 2007; Eastmond et al. 2009; Johnson 2012).
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With reference to chromosomal abnormalities detection,
both structural and numerical changes can be identified
in vitro in metaphase-spread preparations from exposed
mammalian cells. Common in vitro chromosomal damage
tests include the mammalian chromosome aberration test
and the micronucleus test. In the former assay, mammalian
metaphase cells are analyzed for the presence of structural
chromosome aberrations, and in the latter, micronuclei in
the cytoplasm of cultured mammalian cells during inter-
phase is detected. The micronucleus test is a procedure for
the detection of both aneuploidy and clastogenicity in
cultured mammalian cells (Combes et al. 2007; Eastmond
et al. 2009).
Phase 2 in vivo assays can be used in the verification of the
positive results obtained in Phase 1 testing. The common
procedure is searching for cytogenetic damage with the use
of metaphase analysis assay or the micronucleus test. The
in vivo chromosome aberration test in mammals allows the
identification of structural chromosome changes induced by a
substance in the bone marrow cells of animals, whereas the
in vivo micronucleus assay is used for the identification of
genetic changes induced by the tested compound to the chro-
mosomes or the mitotic apparatus of cells by the analysis of
erythrocytes as sampled in the bone marrow and/or peripheral
blood cells of animals. Other in vivo assays include transgenic
animal assays for point mutations, which can be used for the
simultaneous detection of mutagenic effects in various tissues;
DNA strand breakage assays, such as a comet assay (also
referred to as the single-cell gel electrophoresis assay), which
detect single- and double-strand breaks, repair induced breaks
and alkali-labile lesions; and the liver unscheduled DNA
synthesis (UDS) test, which is useful for the measurement of
the repair of DNA lesions (Combes et al. 2007; Eastmond
et al. 2009).
Compounds that give positive results for mutagenic poten-
tial in somatic cells in vivo should be further tested with germ
cells. Germ cell assays available in Phase 3 fall into two
classes. Class 1 includes assays in germ cells per se, such as
gene mutation tests in transgenic animals; paternal germinal
mutation in the expanded simple tandem repeat (ESTR) test;
and chromosomal aberration tests. On the other hand, class 2
contains assays used for the identification of alterations in the
offspring of exposed animals. These studies include i.a. test-
ing for gene mutations in th ESTR assay; mouse visible
specific locus test for detecting and quantifying the induction
of heritable point mutations (intragenic changes and small
deficiencies) in mammals; the biochemical specific locus test
which allows the detection of mutations originating in the
germ line of a mammalian species; and for chromosome or
gene mutations in the dominant lethal test (Verhofstad et al.
2008; Eastmond et al. 2009). Table 3 depicts the characteris-
tics of the most popular bioassays used to assess the mutage-
nicity of compounds.
Antimutagenicity screening assays
Usually, the antimutagenicity assay is done as the appropriate
mutagenicity test, except that the tested cells are treated si-
multaneously with both the test compound and a standard
mutagen. In the early evaluation of the antimutagenic effects
of compounds, basic bacterial short-term assays are used.
These assays have many advantages, including their simplic-
ity, relatively low cost, sensitivity, and flexibility to different
experimental settings (De Flora et al. 1992). In addition, such
tests enable to indicate the possible mechanisms of
antimutagenic activity. Listed below are only the tests that
are most frequently used to screen compounds for
antimutagenic activity.
The Ames test, also known as the Salmonella
typhimurium/microsome assay (Maron and Ames 1983),
is one of the most widely used short-term mutagenicity/
antimutagenicity test. The assay detects the mutagenic po-
tential of tested substances through the induction of reverse
mutations in the his operon of genetically modified
S. typhimurium strains (Maron and Ames 1983;
Mortelmans and Zeiger 2000). The test detects mutagenic
agents acting with different mutation mechanisms, such as
base-pair substitution and frameshift mutations. Moreover,
by using tester strains with different genotypes, the
antimutagenic activity of compounds against mutations
induced by various mutagenic agents that act via different
mechanisms can be evaluated (Mortelmans and Zeiger
2000). Salmonella typhimurium mutagenicity and
antimutagenicity test procedures can all be applicable to
the Escherichia coli WP2 reverse mutation assay. The only
assay difference is the addition of trace amounts of trypto-
phan instead of histidine to the top agar. This assay is
primarily useful in the detection of A/T base pair damage
(Mortelmans and Riccio 2000).
In the last several decades, several rapid bacterial
mutagenicity/antimutagenicity tests have been developed
and optimized, such as the assay based on a marine bacterium
Vibrio harveyi (Czyż et al. 2000, 2002; Piosik et al. 2003;
Węgrzyn and Czyż 2003; Podgórska et al. 2005; Ulanowska
and Węgrzyn 2006; Słoczyńska et al. 2010; Kamiński et al.
2013; Pękala et al. 2013). The test employs a series of genet-
ically modified Vibrio harveyi strains. The bacterium is natu-
rally sensitive to neomycin; however, antibiotic-resistant mu-
tants can be separated. The frequency of appearance of mu-
tants increases in the presence of mutagens in a dose–response
manner, and this forms the basis of this assay.
Another vital tool in antimutagenicity assessment is the
SOS chromotest (Quillardet and Hofnung 1985). As with the
other above-mentioned tests, this test was also developed as
an alternative to the Ames test. The SOS chromotest is a
colorimetric assay that employs Escherichia coli PQ37mutant
strain and allows the assessment of DNA changes induced by
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various mutagens by the measurement of the expression of a
reporter gene, β-galactosidase (Quillardet et al. 1985).
Finally, the antimutagenicity assay on yeasts is also very
popular in searching for new antimutagens. This is mainly due
Table 4 Comparison of the advantages and disadvantages of the most widely used antimutagenicity screening tests
Test name Main advantages Main disadvantages
Salmonella typhimurium assay - Very extensive database available
- Easy to perform
- No special equipment is necessary
- Tester organism is a potentially pathogenic bacterium
- Several tester strains should be used
- A relatively long time necessary to perform the analysis
- Will not detect mutagens that interact with
eukaryote-specific targets
Escherichia coli WP2 assay - Easy to perform
- No special equipment is necessary
- Only one tester strain is needed
- A relatively long time necessary to perform the analysis
- Will not detect mutagens that interact with
eukaryote-specific targets
Vibrio harveyi assay - Relatively low cost
- The simplicity of procedures
- Tester organism is not pathogenic to humans
- May detect significantly lower concentrations
of typical chemical mutagens than the Ames test
- No special equipment is necessary
- Several tester strains should be used
- A relatively long time necessary to perform the analysis
- Will not detect mutagens that interact with
eukaryote-specific targets
SOS chromotest - The simplicity of procedures
- Test rapidity
- Only one tester strain is needed
- Will not detect mutagens that interact with
eukaryote-specific targets
- Special equipment is necessary
Saccharomyces cerevisiae assay - Eukaryotic architecture
- Saccharomyces cerevisiae strains do have
endogenous cytochrome P450
- No special equipment is necessary
- A relatively long time necessary to perform the analysis
Table 3 Characteristics of the most popular bioassays used to assess the mutagenicity of compounds
Phase Test name Endpoint Reference
1 Salmonella typhimurium reverse mutation test Gene mutations in bacteria OECD (1997a) Test Guideline 471
1 Escherichia coli WP2 reverse mutation test Gene mutations in bacteria OECD (1997a) Test Guideline 471
1 In vitro mouse lymphoma test Gene mutations in mammalian cells OECD (1997e) Test Guideline 476
1 Hypoxanthine guanine phosphorybosyl
transferase (HPRT) gene mutation assay
Gene mutations in mammalian cells OECD (1997e) Test Guideline 476
1 In vitro mammalian cell micronucleus test Structural and numerical chromosome alterations OECD (2010) Test Guideline 487
1 In vitro mammalian chromosome aberration test Chromosome aberrations OECD (1997b) Test Guideline 473
1 In vitro comet assay DNA damage Burlinson (2012)
1 Saccharomyces cerevisiae gene mutation assay Gene mutations in yeast OECD (1986a) Test Guideline 480
2 Mammalian erythrocyte micronucleus test Structural and numerical chromosome alterations OECD (1997c) Test Guideline 474
2 Mammalian bone marrow chromosome aberration test Structural chromosome aberrations OECD (1997d) Test Guideline 475
2 Transgenic animal assays for point mutations Gene mutations IWGT Test Guideline
2 In vivo comet assay DNA damage Burlinson et al. (2007)
Burlinson (2012)
2 Unscheduled DNA synthesis (UDS) test with
mammalian liver cells in vivo
DNA damage OECD (1997g) Test Guideline 486
3 Transgenic animal assays for point mutations Gene mutations IWGT Test Guideline
3 DNA mutation in expanded simple tandem
repeat (ESTR) test
Singer et al. (2006)
3 Mammalian spermatogonial chromosome aberration test Structural chromosome aberrations OECD (1997f) Test Guideline 483
3 Mouse visible specific locus test Gene mutations Russell et al. (1981)
3 Mouse biochemical specific locus (MBSL) test Gene mutations Lewis et al. (1986)
3 Rodent dominant lethal test Gene mutations and chromosome changes OECD (1984) Test Guideline 478
3 Mouse heritable translocation assay Structural and numerical chromosome changes OECD (1986b)Test Guideline 485
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to the fact that yeasts as eukaryotes are characterized with
chromosome structure and DNA repair processes similar to
those in mammals. Furthermore, Saccharomyces cerevisiae
strains are equipped with endogenous cytochrome P450,
and, therefore, can be very useful when testing promutagens
(Zimmermann et al. 1975). Table 4 provides an overview of
the main advantages and disadvantages of the most popular
tests used in preliminary antimutagenicity assessment.
Conclusions
Mutagenic activity is one of the most important endpoints for
the risk assessment of chemical compounds, including drug
substances and drug candidates, as mutagens are capable of
inducing various kinds of changes in the genetic material of a
cell. On the other hand, the mutagenic effects of some
chemicals may be partly modulated or reduced by the use of
compounds presenting antimutagenic properties.
Research over the past few years has revealed that mutation
has a key role in carcinogenesis. Therefore, one may expect
that searching for compounds with antimutagenic potency will
remain in the focus of research in the near future. Research
studies on antimutagenicity should be focused primarily on the
understanding of the mode of action of the most active com-
pounds. Furthermore, there is still much more research needed
in order to clear up the exact links between the results of the
short-term antimutagenicity studies and anticarcinogenicity
experiments in animal models.
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